Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 246

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 8
Chunk 246
---
 The following sets forth information regarding the balances and activity associated with the Company’s accrued employee severance and benefits costs (in thousands): 

        Balance as of December 31, 2023

        Expenses, net

        Cash

        Balance as of December 31, 2024

        Employee severance and benefit costs
         
        —

        597

        (597
        )

        —

13.  Segment InformationThe Company has viewed its operations and manages its business as one operating and reporting segment. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the Company’s CODM to make decisions with respect to resource allocation and assessment of performance. The Company’s CODM is its Chief Executive Officer, who reviews and evaluates consolidated net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO.The CEO regularly reviews the Consolidated Statement of Operations and a disaggregation of operating expenses, of which the significant expenses are related to research and development. The following table represents the significant segment expenses regularly provided to the CEO:  

        Year Ended

        December 31,

        2024

        2023

        2022

        Research and Development

        Research
         
        $
        5,914

        $
        5,307

        $
        6,712

        Development

        35,295

        31,740

        32,470

        Personnel related

        13,662

        13,320

        9,341

        Stock-based compensation

        3,656

        5,518

        3,465

        Total research and development

        58,527

        55,885

        51,988

        General and administration

        Personnel related
         
        $
        5,849

        $
        6,748

        $
        6,649

        Stock-based compensation

        5,216

        6,857

        6,729

        External

        15,856

        10,642

        11,674

        Total general and administrative

        26,921

        24,247

        25,052

        Loss from Operations
         
        $
        85,448